Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

Market Cap	64.65B -6.4%
Revenue (ttm)	31.37B +2.2%
Net Income	3.99B -19.3%
EPS	95.84 -19.3%
Shares Out	41.63M
PE Ratio	16.20
Forward PE	14.07
Dividend	50.00 (3.22%)
Ex-Dividend Date	Mar 30, 2026

Volume	118,900
Average Volume	226,890
Open	1,520.00
Previous Close	1,559.00
Day's Range	1,520.00 - 1,574.00
52-Week Range	1,142.00 - 2,005.00
Beta	-0.44
RSI	42.63
Earnings Date	May 8, 2026

About TYO:2395

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,532
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2395

Financial Performance

In fiscal year 2025, TYO:2395's revenue was 32.41 billion, an increase of 22.54% compared to the previous year's 26.45 billion. Earnings were 4.92 billion, a decrease of -10.97%.